We are pleased to share an expert discussion with Dr. Peter Schmid on the findings from the pivotal Keynote 522 trial. This landmark Phase 3 study investigates the impact of combining chemotherapy with immunotherapy (Pembrolizumab) in early-stage triple-negative breast cancer (TNBC). The trial’s results highlight a 34% reduction in the risk of death, marking a significant advancement in patient outcomes and offering new hope for TNBC treatment strategies.

In the past, there has been ongoing debate about the therapeutic value of radiotherapy in resectable gastric cancer. The TOPGEAR study presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona) evaluated the comparison between preoperative chemoradiotherapy and perioperative chemotherapy alone. Dr. Trevor Leong, the Principal Investigator from the University of Melbourne in Australia, was interviewed by us on site.

The DESTINY-Gastric03 study (abstract number 14010), presented at the 2024 European Society for Medical Oncology (ESMO) Congress (September 13-17, Barcelona), evaluated the efficacy and safety of T-DXd combined with FP and anti-PD-1 as first-line treatment for adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJA). At the conference site, we specially invited the Principal Investigator, Dr. Yelena Janjigian from Memorial Sloan Kettering Cancer Center in the United States, to be interviewed by us on site.

At the 2024 ESMO annual meeting, Benoit You from the Lyon Sud Hospital Center, France, presented the results of the phase I/II TROPHAMET trial (abstract number 711O) in the preferred oral report session and was interviewed by Oncology Frontier.